Kingdon Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Kingdon Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-843,940	Closed	-$9.93M	–	78
2020 Q3	$9.93M	Sell	843,940 -320,403	-28%	-$3.9M	1.12%	30
2020 Q2	$17.2M	Hold	1,164,343	–	–	1.56%	16
2020 Q1	$15.7M	Sell	1,164,343 -60,482	-5%	-$1.15M	2.88%	8
2019 Q4	$29.6M	Buy	1,224,825 +414,337	+51%	+$8.58M	4.46%	7
2019 Q3	$15.6M	Buy	+810,488	New	+$18.6M	1.84%	22

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Kingdon Capital Management's AERI Position: Q4 2020 in Review

Kingdon Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2020, closing a stake of 843,940 shares — an estimated $9.93M sold.

Kingdon Capital Management first reported a position in AERI in Q3 2019 and held it in 5 quarters. The position peaked at $29.6M in Q4 2019. 150 funds tracked by Wall St. Rank hold AERI as of Q4 2020.

Kingdon Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Kingdon Capital Management sold 843,940 Aerie Pharmaceuticals shares in Q4 2020, an estimated $9.93M.
Kingdon Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 5 quarters.
Kingdon Capital Management's Aerie Pharmaceuticals position peaked at $29.6M in Q4 2019.
150 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2020.

Based on Kingdon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.